Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2000 6
2001 1
2002 1
2003 2
2004 1
2005 7
2006 7
2007 11
2008 6
2009 6
2010 6
2011 7
2012 22
2013 21
2014 20
2015 25
2016 30
2017 36
2018 15
2019 4
2020 1
2021 4
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Montalban X, et al. Among authors: havrdova e. Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Mult Scler. 2018. PMID: 29353550
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Polman CH, et al. Among authors: havrdova e. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366. Ann Neurol. 2011. PMID: 21387374 Free PMC article.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. Among authors: havrdova e. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Montalban X, et al. Among authors: havrdova e. Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Eur J Neurol. 2018. PMID: 29352526 Free article.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. Among authors: havrdova e. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Free article. Clinical Trial.
Defining secondary progressive multiple sclerosis.
Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group. Lorscheider J, et al. Among authors: havrdova e. Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7. Brain. 2016. PMID: 27401521 Free article.
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J. Kappos L, et al. Among authors: havrdova e. Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1. Lancet Neurol. 2011. PMID: 21777829 Free article. Review.
Time course of lesion-induced atrophy in multiple sclerosis.
Carolus K, Fuchs TA, Bergsland N, Ramasamy D, Tran H, Uher T, Horakova D, Vaneckova M, Havrdova E, Benedict RHB, Zivadinov R, Dwyer MG. Carolus K, et al. Among authors: havrdova e. J Neurol. 2022 Aug;269(8):4478-4487. doi: 10.1007/s00415-022-11094-y. Epub 2022 Apr 8. J Neurol. 2022. PMID: 35394170
209 results